Ghent University Academic Bibliography

Advanced

Exhaled breath to screen for malignant pleural mesothelioma : a validation study

Kevin Lamote UGent, Matthijs Vynck UGent, Olivier Thas UGent, Joris Van Cleemput, Kristiaan Nackaerts and Jan Van Meerbeeck UGent (2017) EUROPEAN RESPIRATORY JOURNAL. 50(6).
abstract
Malignant pleural mesothelioma (MPM) is predominantly caused by asbestos exposure and has a poor prognosis. Breath contains volatile organic compounds (VOCs) and can be explored as an early detection tool. Previously, we used multicapillary column/ion mobility spectrometry (MCC/IMS) to discriminate between patients with MPM and asymptomatic high-risk persons with a high rate of accuracy. Here, we aim to validate these findings in different control groups. Breath and background samples were obtained from 52 patients with MPM, 52 healthy controls without asbestos exposure (HC), 59 asymptomatic former asbestos workers (AEx), 41 patients with benign asbestos-related diseases (ARD), 70 patients with benign non-asbestos-related lung diseases (BLD) and 56 patients with lung cancer (LC). After background correction, logistic lasso regression and receiver operating characteristic (ROC) analysis, the MPM group was discriminated from the HC, AEx, ARD, BLD and LC groups with 65%, 88%, 82%, 80% and 72% accuracy, respectively. Combining AEx and ARD patients resulted in 94% sensitivity and 96% negative predictive value (NPV). The most important VOCs selected were P1, P3, P7, P9, P21 and P26. We discriminated MPM patients from at-risk subjects with great accuracy. The high sensitivity and NPV allow breath analysis to be used as a screening tool for ruling out MPM.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
ORGANIC-COMPOUNDS VOCS, LUNG-CANCER, ELECTRONIC NOSE, DIAGNOSIS, BIOMARKER, ARRAY
journal title
EUROPEAN RESPIRATORY JOURNAL
Eur. Resp. J.
volume
50
issue
6
article number
1700919
pages
11 pages
Web of Science type
Article
Web of Science id
000423716000005
ISSN
0903-1936
1399-3003
DOI
10.1183/13993003.00919-2017
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
8543145
handle
http://hdl.handle.net/1854/LU-8543145
date created
2017-12-23 15:34:09
date last changed
2018-03-01 12:02:38
@article{8543145,
  abstract     = {Malignant pleural mesothelioma (MPM) is predominantly caused by asbestos exposure and has a poor prognosis. Breath contains volatile organic compounds (VOCs) and can be explored as an early detection tool. Previously, we used multicapillary column/ion mobility spectrometry (MCC/IMS) to discriminate between patients with MPM and asymptomatic high-risk persons with a high rate of accuracy. Here, we aim to validate these findings in different control groups. 
Breath and background samples were obtained from 52 patients with MPM, 52 healthy controls without asbestos exposure (HC), 59 asymptomatic former asbestos workers (AEx), 41 patients with benign asbestos-related diseases (ARD), 70 patients with benign non-asbestos-related lung diseases (BLD) and 56 patients with lung cancer (LC). 
After background correction, logistic lasso regression and receiver operating characteristic (ROC) analysis, the MPM group was discriminated from the HC, AEx, ARD, BLD and LC groups with 65\%, 88\%, 82\%, 80\% and 72\% accuracy, respectively. Combining AEx and ARD patients resulted in 94\% sensitivity and 96\% negative predictive value (NPV). The most important VOCs selected were P1, P3, P7, P9, P21 and P26. 
We discriminated MPM patients from at-risk subjects with great accuracy. The high sensitivity and NPV allow breath analysis to be used as a screening tool for ruling out MPM.},
  articleno    = {1700919},
  author       = {Lamote, Kevin and Vynck, Matthijs and Thas, Olivier and Van Cleemput, Joris and Nackaerts, Kristiaan and Van Meerbeeck, Jan},
  issn         = {0903-1936},
  journal      = {EUROPEAN RESPIRATORY JOURNAL},
  keyword      = {ORGANIC-COMPOUNDS VOCS,LUNG-CANCER,ELECTRONIC NOSE,DIAGNOSIS,BIOMARKER,ARRAY},
  language     = {eng},
  number       = {6},
  pages        = {11},
  title        = {Exhaled breath to screen for malignant pleural mesothelioma : a validation study},
  url          = {http://dx.doi.org/10.1183/13993003.00919-2017},
  volume       = {50},
  year         = {2017},
}

Chicago
Lamote, Kevin, Matthijs Vynck, Olivier Thas, Joris Van Cleemput, Kristiaan Nackaerts, and Jan Van Meerbeeck. 2017. “Exhaled Breath to Screen for Malignant Pleural Mesothelioma : a Validation Study.” European Respiratory Journal 50 (6).
APA
Lamote, K., Vynck, M., Thas, O., Van Cleemput, J., Nackaerts, K., & Van Meerbeeck, J. (2017). Exhaled breath to screen for malignant pleural mesothelioma : a validation study. EUROPEAN RESPIRATORY JOURNAL, 50(6).
Vancouver
1.
Lamote K, Vynck M, Thas O, Van Cleemput J, Nackaerts K, Van Meerbeeck J. Exhaled breath to screen for malignant pleural mesothelioma : a validation study. EUROPEAN RESPIRATORY JOURNAL. 2017;50(6).
MLA
Lamote, Kevin, Matthijs Vynck, Olivier Thas, et al. “Exhaled Breath to Screen for Malignant Pleural Mesothelioma : a Validation Study.” EUROPEAN RESPIRATORY JOURNAL 50.6 (2017): n. pag. Print.